Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that, as result of court mediation proceedings, it has entered into a written agreement in principle with the Court-appointed lead plaintiffs to settle all of the currently pending securities class actions consolidated in the U.S. District Court for the Eastern District of Pennsylvania. The proposed settlement requires formal court approval. The class actions have been stayed by the Court pending those mandatory procedures needed to formalize and approve the settlement. The settlement will be paid from the company's insurance coverage and will not result in the payment of any funds by the Company. Furthermore, the settlement expressly is not an admission of any culpability by Hemispherx or its officers. Thomas K. Equels, General Counsel, stated: "We at Hemispherx look forward to Court approval of this settlement. Our team will be glad to have these class actions behind us so that we can focus our time and resources on the important work of new drug development related to Ampligen® for CFS, important flu related clinical trials, and the manufacturing and marketing of our FDA approved anti-viral Alferon®."